

Fig. 4. Comparison between the abdominal skin and the ear skin for determining the most suitable target site for prolonged TCI. The bare abdominal skins or the dorsal side of the left ears of C57BL/6 mice ($n=5$) were immunized by non-adjuvanted prolonged TCI procedure with 10 or 100 µg of OVA for 16 h. Immunization of each group of mice was performed in an identical manner at 0, 2, and 4 weeks. OVA-specific IgG titres in serum samples were determined at 6 weeks after the primary immunization. The geometric means and the standard error of the means are shown for each group.

2 weeks after the last immunization. We found that, with both doses of OVA, the immunization of the dorsal sides of ears induced higher titres of antibodies than that of the bare abdominal skin (Fig. 4). Thus, the prolonged TCI procedure immunized the ear skin more efficiently than the abdominal skin.

3.3. Non-adjuvanted prolonged TCI of the ear skin induced a serum antibody response comparable induced by the adjuvanted TCI

We compared the serum antibody responses induced by the non-adjuvanted prolonged TCI and adjuvanted TCI by using dose–response and time-course studies.

Patches containing 1.0, 12.5, 25, 50, or 100 µg of OVA and with or without 10 µg of CT were taped to the dorsal side of the ears of the C57BL/6 mice for 16 h according to the prolonged TCI procedure. We boosted the mice twice with 2-week intervals in a manner identical to that used for the primary immunization and determined the serum OVA-specific IgG antibody titres 2 weeks after the last immunization. The titres of the serum IgG antibodies increased in a dose-dependent manner, and there was no significant difference between the magnitudes of the serum antibody response induced by the non-adjuvanted prolonged TCI and that induced by the adjuvanted TCI (Fig. 5A).

In the time-course experiment, we immunized the ears of the C57BL/6 mice with 100 µg of OVA with or without 10 µg of CT according to the prolonged TCI procedure and boosted the mice twice at 2-week intervals in a manner identical to that used for the primary immunization. We collected serum samples prior to the immunization and every week for 1–6 weeks after the primary immunization. Further, we determined the time-course of the OVA-specific IgG antibody productions. Significant serum anti-OVA antibody production was observed after the first booster immunization, and this production was enhanced by the second booster immunization. There were no significant differences between the serum antibody responses induced by the non-adjuvanted prolonged TCI and the adjuvanted one, except with regard to




Fig. 5. Dose–response (A) and time-course (B) of serum antibody production by the non-adjuvanted or adjuvanted prolonged TCI procedure. (A) The ears of C57BL/6 mice ($n=5$) were immunized by prolonged TCI procedure for 16 h with the indicated doses of OVA from 1.0 to 100 µg with (hatched bars) or without (solid bars) 10 µg of CT as an adjuvant. Each group of mice was immunized in an identical manner at 0, 2, and 4 weeks. OVA-specific IgG titres in serum samples were determined at 6 weeks after the primary immunization using ELISA. The geometric mean and the standard error of the mean are shown for each group. (B) The ears of C57BL/6 mice ($n=5$) were immunized by the prolonged TCI procedure for 16 h with 100 µg of OVA with (closed triangles and a broken line) or without (closed circles and an unbroken line) 10 µg of CT as an adjuvant at 0, 2, and 4 weeks. OVA-specific IgG titres in serum samples were determined every week up to 6 weeks after the primary immunization. The geometric means and the standard error of the means are shown for each group and time.




Fig. 6. Fecal antibody responses induced by the non-adjuvanted or adjuvanted prolonged TCI procedure. The ears of C57BL/6 mice ($n=5$) were immunized by prolonged TCI procedure for 16 h with 100 μg of OVA with or without 10 μg of CT as an adjuvant at 0, 2, and 4 weeks. Another group of mice ($n=5$) was inoculated nothing as a negative control. The fecal samples were collected at 6 weeks after the primary immunization and OVA-specific IgG (A) and IgA (B) titers in the fecal extracts were determined. The geometric means and the standard error of the means are shown for each group.

the antibody titres at 6 weeks after the primary immunization (Fig. 5B).

Thus, the non-adjuvanted prolonged TCI comprising the 16-h antigen presence induced serum antigen-specific antibody responses of a level comparable to that observed with the adjuvanted TCI.

3.4. Non-adjuvanted prolonged TCI induced significant fecal antibody responses

Previous studies demonstrated that CT-adjuvanted TCI elicited not only systemic but also mucosal antibody responses. We examined the fecal IgG and IgA antibody responses after adjuvanted and non-adjuvanted TCI.

Patches containing 100 μg of OVA and with or without 10 μg of CT were applied to the dorsal side of the ears of the C57BL/6 mice for 16 h. We boosted the mice twice with 2-week intervals in a manner identical to that used for the primary immunization. Other group of mice were inoculated nothing as a negative control. We collected the fecal samples at 2 weeks after the last immunization.

Both groups of the immunized mice produced significant fecal IgG and IgA antibodies (Fig. 6). The CT-adjuvanted TCI group indicated approximately 4-fold higher titers of antibody production than the non-adjuvanted group.

3.5. Non-adjuvanted prolonged TCI of the ear skin induced a significant serum antibody response, regardless of mice strains

We examined strain differences with regard to the serum antibody responses induced by the prolonged TCI procedure. The ears of the C57BL/6, BALB/c, or C3H/He mice were immunized with 100 μg of OVA with or without 10 μg of CT according to the prolonged TCI procedure. The mice were boosted twice at 2-week intervals, and

the OVA-specific IgG antibody production in their sera was determined 2 weeks after the last immunization. We observed significant differences in the magnitude of the serum OVA-specific IgG antibody responses among the different strains of mice. Among the 3 strains, the C57BL/6 mice produced the highest amounts of serum antigen-specific IgG antibodies, while the C3H/He mice produced the least amounts. Besides, both the non-adjuvanted prolonged TCI and the adjuvanted one induced substantial serum antibody responses in all the strains of mice that were examined (Fig. 7).




Fig. 7. Differences between the mice strains with regard to the serum antigen-specific IgG responses induced by the non-adjuvanted or adjuvanted prolonged TCI procedure. The ears of C57BL/6 ($n=5$), BALB/c ($n=5$), or C3H/He ($n=5$) mice were immunized with 100 μg of OVA with (hatched bars) or without (solid bars) 10 μg of CT as an adjuvant according to the prolonged TCI procedure for 16 h at 0, 2, and 4 weeks. OVA-specific IgG titres in serum samples were determined at 6 weeks after the primary immunization. The geometric means and the standard error of the means are shown for each group.




Fig. 8. Immunization using the tetanus toxoid (Ttd) for the prolonged TCI procedure with or without adjuvant. The ears of C57BL/6 mice ($n=5$, but $n=4$ for the "with adjuvant" group) were immunized by the prolonged TCI procedure for 16 h with 10 Lf of Ttd with (closed triangles and a broken line) or without (closed circles and an unbroken line) 10 μg of CT as an adjuvant at 0, 2, and 4 weeks. The negative controls were immunized with 10 μg of CT (reverse closed triangles and an unbroken line) or vehicle (PBS) alone (open circles and an unbroken line) in an identical manner. OVA-specific IgG titres in serum samples were determined every 2 weeks for up to 6 weeks after the primary immunization. The geometric means and the standard error of the means are shown for each group and time.

3.6. Prolonged TCI using the Ttd induced a robust antibody response and provided protection against tetanus toxin challenge

We immunized the ears of the C57BL/6 mice with 10 flocculation units (Lf) of Ttd with or without 10 μg of CT according to the prolonged TCI procedure. As controls, we also immunized another group of mice with 10 μg of CT or vehicle (PBS) alone. We boosted the mice twice at 2-week intervals in a manner identical to that used for the primary immunization. We collected serum samples every alternate week for up to 6 weeks after the primary immunization and determined the titres of Ttd-specific IgG antibodies in the sera. Regardless of the use of the adjuvant, significant levels of Ttd-specific IgG antibodies were induced in the sera of the mice immunized with the Ttd, and these levels increased after the booster immunizations (Fig. 8). In contrast, in the mice immunized with either the CT or vehicle

Table 1
Tetanus toxin challenge^a

	Survival/total	% Survival
Saline	0/5	0
CT	0/5	0
Ttd	5/5	100
Ttd + CT	4/4	100

^a C57BL/6 mice were immunized by prolonged TCI procedure with 10 Lf of Ttd with or without 10 μg of CT at 0, 2, 4 weeks. Ten micrograms of CT or vehicle (saline) alone were immunized to the other groups of mice by the same way. Ten LD50 of tetanus toxins were challenged at 7 weeks after primary immunization.

alone, no Ttd-specific IgG antibodies were induced at all the times examined.

Next, we challenged these mice with a lethal dose of tetanus toxin at 7 weeks after the primary immunization. All the control mice (only CT or vehicle immunized) died within 2 days of the challenge with signs of tetanus (Table 1). In contrast, all the mice immunized with the Ttd survived and demonstrated no clinical signs regardless of adjuvant use.

4. Discussion

In the recent decade, many studies have demonstrated the feasibility of TCI using various antigens [3–7], adjuvants [10,13–16], skin treatments [7,17–19], and animals [20–24]. Under these various settings, most experiments followed a protocol in which antigens were topically applied for 1–2 h and reported the critical role of adjuvants for the induction of robust immune responses. Skin pretreatments such as skin abrasion [25], application of penetration enhancers [7,26], use of electrophoresis [17] or sonophoresis [18] techniques, and the use of lipid carriers [20,27] were applied in some experiments; these pretreatments might promote antigen penetration through the skin. Overall, some potent adjuvants and/or some skin penetration-enhancing methods are believed to be necessary to induce robust immune responses by TCI. Nevertheless, a few papers [28–30] reported that substantial immune responses were successfully induced in the absence of any adjuvants or penetration-enhancing methods. Further, in all of these experiments, the antigens were applied topically for a comparatively long-period of above over night. These results suggest that the duration of antigen presence on the skin during the TCI procedure might be an important parameter affecting the magnitude of the immune responses. However, thus far, the relationship between the duration of antigen presence on the skin and the magnitude of the immune response remains to be clearly elucidated. In this report, we applied OVA as an antigen for varying durations of 2–32 h on the intact skin of mice and observed that if the antigen was present on the skin for a prolonged duration, the serum antibody response was enhanced in a duration-dependent manner. Surprisingly, patch immunization on intact skin for above 16 h (referred to as prolonged TCI in this paper) induced substantial serum antibody responses even in the absence of any adjuvants. Dose–response and time-course experiments revealed that non-adjuvanted prolonged TCI to the mice ear induced serum antibody responses comparable in magnitude to those induced by adjuvanted prolonged TCI. Thus, our observations clearly indicated that the duration of antigen presence on the skin is an important factor influencing the effectiveness of TCI.

Several reports assume that some danger signals from bacterial adjuvants are necessary to activate Langerhans cells and trigger immune responses [8]. However, our data indicate that additional adjuvants are not prerequisites for the induction of immune responses. This result might imply that the antigen

itself stimulates the Langerhans cells or that some substances from skin bacterial flora play the role of danger signals. It is possible that a wet gauze patch stuck on the stratum corneum for a prolonged period stimulates the Langerhans cells. In fact, there are reports that some physical stimuli to the stratum corneum, such as tape-stripping or low frequency ultrasound, activate the Langerhans cells [18,37].

Our experiments clearly indicated that the ear skin was immunized more efficiently than the abdominal skin by the prolonged TCI procedure. It is known that the differences in skin structure, such as thickness of the stratum corneum and the density of Langerhans cells, among anatomic skin sites influence the penetration efficiency of low molecular percutaneous drugs [31,32]. The difference between the structures of the ear skin and abdominal skin may explain our observation. Thus, our observation indicates that skin anatomy is an important factor influencing the efficiency of TCI.

CT or LT has strong mucosal adjuvanticity. CT-adjuvanted or LT-adjuvanted TCI induces the mucosal antibody response, in addition to the systemic immune response [6,7,15,28,33,34]. Interestingly, we observed that non-adjuvanted prolonged TCI with OVA induced substantial antigen-specific IgG and IgA antibodies in the feces of mice although the magnitude of antibody production was significantly less as compared to that induced by CT-adjuvanted TCI. Our observation indicated that the mucosal immune response to TCI could be also induced even in the absence of CT or LT.

We observed substantial antibody responses in all the 3 strains of mice immunized by the prolonged non-adjuvanted TCI. This observation suggests that this modified TCI would be feasible for a wide range of genetic backgrounds. However, there were some significant differences among the 3 strains with regard to the magnitude of serum antibody productions. The C57BL/6 mice were the most sensitive to the prolonged TCI, while the C3H/He mice were the least sensitive. The response of the BALB/c mice was intermediate. Another group has previously reported a similar hierarchy in the sensitivity to TCI [38]. They used CT as an adjuvant and hypothesized that the hierarchy reflected the difference in the sensitivity to CT based on former experiments which indicated that the plasma IgG response to CT following oral or parenteral administration was under the genetic control of the I-A region of the H-2 major histocompatibility complex [39–41]. Here, we observed the same hierarchy regardless of the use of CT, suggesting that other mechanism(s) govern the sensitivity to TCI.

We applied the prolonged TCI method by using the Ttd as a model vaccine antigen and successfully induced significant serum antibody responses. Indeed, CT had an adjuvant effect in the prolonged TCI using Ttd, but non-adjuvanted prolonged TCI using the Ttd also induced substantial Ttd-specific antibodies in the sera of mice after the second booster immunization. The mice immunized with the Ttd according to the prolonged TCI method, adjuvanted and non-adjuvanted, survived with no clinical symptoms after

challenge with a lethal dose of the tetanus toxin. These results suggest that non-adjuvanted prolonged TCI method is a feasible vaccination method for infectious diseases.

Thus far, the TCI method has been shown to be functional in various disease models, including bacterial and viral infections, malignancies [26,35], and Alzheimer's disease [36], using various animals, e.g., mice, rats [20], sheep [22], cattle [24], chickens [21], and humans [12,19]. To develop an effective TCI strategy for different aims, the TCI protocol with regard to antigens, adjuvants, skin treatments, etc. requires optimization. In this study, we pointed out the importance of the duration of antigen presence on the skin during the TCI procedure and showed that substantial antibodies were induced by non-adjuvanted TCI of 16-h duration. Our observations improve the understanding regarding the TCI mechanisms and offer a practical option for developing a safe and effective method for transcutaneous vaccination.

References

- [1] Bos JD. The skin as an organ of immunity. *Clin Exp Immunol* 1997;107(Suppl. 1):3–5.
- [2] Chuong CM, Nickoloff BJ, Elias PM, Goldsmith LA, Macher E, Maderison PA, et al. What is the 'true' function of skin? *Exp Dermatol* 2002;11:159–87.
- [3] Glenn GM, Rao M, Matyas GR, Alving CR. Skin immunization made possible by cholera toxin. *Nature* 1998;391:851.
- [4] Beignon AS, Briand JP, Muller S, Partidos CD. Immunization onto bare skin with heat-labile enterotoxin of *Escherichia coli* enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge. *Immunol* 2001;102:344–51.
- [5] Godefroy S, Goestch L, Plotnicky-Gilquin H, Nguyen TN, Schmitt D, Staquet MJ, et al. Immunization onto shaved skin with a bacterial enterotoxin adjuvant protects mice against Respiratory Syncytial Virus (RSV). *Vaccine* 2003;21:1665–71.
- [6] Berry LJ, Hickey DK, Skelding KA, Bao S, Rendina AM, Hansbro PM, et al. Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against *Chlamydia muridarum* genital tract infection. *Infect Immun* 2004;72(2):1019–28.
- [7] Skountzou I, Quan FS, Jacob J, Compans RW, Kang SM. Transcutaneous immunization with inactivated influenza virus induces protective immune responses. *Vaccine* 2006;24:6110–9.
- [8] Hammond SA, Guebre-Xabier M, Yu J, Glenn GM. Transcutaneous immunization: an emerging route of immunization and potent immunostimulation strategy. *Crit Rev Ther Drug Carrier Syst* 2001;18(5):503–26.
- [9] Partidos CD, Beignon AS, Briand JP, Muller S. Modulation of immune responses with transcutaneously deliverable adjuvants. *Vaccine* 2004;22:2385–90.
- [10] Glenn GM, Scharton-Kersten T, Vassell R, Matyas GR, Alving CR. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. *Infect Immun* 1999;67(3):1100–6.
- [11] Warger T, Schild H, Rechtsteiner G. Initiation of adaptive immune responses by transcutaneous immunization. *Immunol Lett* 2007;109:13–20.
- [12] Glenn GM, Taylor DN, Li X, Frankel S, Montemarano A, Alving CR. Transcutaneous immunization: a human vaccine delivery strategy using a patch. *Nature Med* 2000;6(12):1403–6.
- [13] Rechtsteiner G, Warger T, Osterloh P, Schild H, Radsak MP. Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod. *J Immunol* 2005;174(5):2476–80.

- [14] Tierney R, Beignon AS, Rappuoli R, Muller S, Searadic D, Partidos CD. Transcutaneous immunization with tetanus toxoid and mutants of *Escherichia coli* heat-labile enterotoxin as adjuvants elicits strong protective antibody. *J Infect Dis* 2003;188(5):753–8.
- [15] John M, Bridges EA, Miller AO, Calderwood SB, Ryan ET. Comparison of mucosal and systemic humoral immune responses after transcutaneous and oral immunization strategies. *Vaccine* 2002;20(21–22):2720–6.
- [16] Scharton-Kersten T, Yu J, Vassell R, O'Hagan D, Alving CR, Glenn GM. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. *Infect Immun* 2000;68(9):5306–13.
- [17] Zhao YL, Murthy SN, Manjili MH, Guan LJ, Sen A, Hui SW. Induction of cytotoxic T-lymphocytes by electroporation-enhanced needle-free skin immunization. *Vaccine* 2006;24(9):1282–90.
- [18] Tezel A, Paliwal S, Shen Z, Mitragori S. Low-frequency ultrasound as a transcutaneous immunization adjuvant. *Vaccine* 2005;23:3800–7.
- [19] Mckenzie R, Bourgeois AL, Frech SA, Flyer DC, Bloom A, Kazempour K, et al. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic *Escherichia coli* (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. *Vaccine* 2007;25(18):3684–91.
- [20] Mishra V, Mahor S, Rawat A, Dubey P, Gupta PN, Singh P, et al. Development of novel fusogenic vesosomes for transcutaneous immunization. *Vaccine* 2006;24(27–28):5559–70.
- [21] Heckert RA, Elankumaran S, Oshop GL, Vakharia VN. A novel transcutaneous plasmid-dimethylsulfoxide delivery technique for avian nucleic acid immunization. *Vet Immunol Immunopathol* 2002;89(1–2):67–81.
- [22] Chen D, Colditz IG, Glenn GM, Tsonis CG. Effect of transcutaneous immunization with co-administered antigen and cholera toxin on systemic and mucosal antibody responses in sheep. *Vet Immunol Immunopathol* 2002;86(3–4):177–82.
- [23] Yu J, Cassels F, Scharton-Kersten T, Hammond SA, Hartman A, Angov E, et al. Transcutaneous immunization using colonization factor and heat-labile enterotoxin induces correlates of protective immunity for enterotoxigenic *Escherichia coli*. *Infect Immun* 2002;70(3):1056–68.
- [24] Morrow CK, Colditz IG, Cope RB. Stimulated solar UVB exposure inhibits transcutaneous immunization to cholera toxin via an irradiated skin site in cattle. *Vet Immunol Immunopathol* 2001;83(1–2):107–14.
- [25] Godefroy S, Peyre M, Garcia N, Muller S, Searadic D, Partidos CD. Effect of skin barrier disruption on immune responses to topically applied cross-reacting material, CRM(197), of diphtheria toxin. *Infect Immun* 2005;73(8):4803–9.
- [26] Frankenburg S, Grinberg I, Bazak Z, Fingerut L, Pitcovski J, Gorodetsky R, et al. Immunological activation following transcutaneous delivery of HR-gp100 protein. *Vaccine* 2007;25(23):4564–70.
- [27] Paul A, Ceve G, Bachhawat BK. Transdermal immunization with an integral membrane component, gap junction protein, by means of ultradeformable drug carriers, transfersomes. *Vaccine* 1998;16(2–3):188–95.
- [28] Ghose C, Kalsy A, Sheikh A, Rollenhagen J, John M, Young J, et al. Transcutaneous immunization with *Clostridium difficile* toxin A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice. *Infect Immun* 2007;75(6):2826–32.
- [29] Matyas GR, Friedlander AM, Glenn GM, Little S, Yu J, Alving CR. Needle-free skin patch vaccination method for anthrax. *Infect Immun* 2004;72(2):1181–3.
- [30] Baca-Estrada ME, Ewen C, Mahony D, Babiuk LA, Wilkie D, Foldvari M. The haemopoietic growth factor, Flt3L, alters the immune response induced by transcutaneous immunization. *Immunology* 2002;107(1):69–76.
- [31] Ya-Xian Z, Suetake T, Tagami H. Number of cell layers of the stratum corneum in normal skin—relationship to the anatomical location on the body, age, sex and physical parameters. *Arch Dermatol Res* 1999;291:555–9.
- [32] Bronaugh RL, Maibach HI. Topical absorption of dermatological products. New York: Marcel Dekker, Inc.; 2002.
- [33] Hickey DK, Bao S, Ikeda LT, Carey AJ, Beagley KW. Induction of anti-chlamydial mucosal immunity by transcutaneous immunization is enhanced by topical application of GM-CSF. *Curr Mol Med* 2005;5(6):599–605.
- [34] Partidos CD, Moreau E, Chaloin O, Tunis M, Briand JP, Desgranges C, et al. A synthetic HIV-1 Tat protein breaches the skin barriers and elicits Tat-neutralizing antibodies and cellular immunity. *Eur J Immunol* 2004;34(12):3723–31.
- [35] Seo N, Tokura Y, Nishijima T, Hashizume H, Furukawa F, Takigawa M. Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis. *Proc Natl Acad Sci USA* 2000;97(1):371–6.
- [36] Nikolic WV, Bai Y, Obregon D, Hou H, Mori T, Zeng J, et al. Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage. *Proc Natl Acad Sci USA* 2007;104(7):2507–12.
- [37] Nishijima T, Tokura Y, Imokawa G, Seo N, Furukawa F, Takigawa M. Altered permeability and disordered cutaneous immunoregulatory function in mice with acute barrier disruption. *J Invest Dermatol* 1997;109(2):175–82.
- [38] Scharton-Kersten T, Glenn GM, Vassell R, Yu J, Walwender D, Alving CR. Principles of transcutaneous immunization using cholera toxin as an adjuvant. *Vaccine* 1999;17:S37–43.
- [39] Elson CO, Ealding W. Genetic control of the murine immune response to cholera toxin. *J Immunol* 1985;135:930–2.
- [40] Elson CO, Ealding W. Ir gene control of the murine secretory IgA response to cholera toxin. *Eur J Immunol* 1987;17:425–8.
- [41] Elson CO. Cholera toxin as a mucosal adjuvant: effects of H-2 major histocompatibility complex and Igs genes. *Infect Immun* 1992;60:2874–9.




ELSEVIER

available at www.sciencedirect.com



journal homepage: www.elsevier.com/locate/vaccine



Application of complementary DNA microarray technology to influenza A/Vietnam/1194/2004 (H5N1) vaccine safety evaluation

Takuo Mizukami^{a,1}, Jun-ichi Imai^{b,1}, Isao Hamaguchi^{a,1}, Mika Kawamura^{b,c}, Haruka Momose^a, Seishiro Naito^a, Jun-ichi Maeyama^a, Atsuko Masumi^a, Madoka Kuramitsu^a, Kazuya Takizawa^a, Nobuo Nomura^d, Shinya Watanabe^b, Kazunari Yamaguchi^{a,*}

^a Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama, Tokyo 208-0011, Japan

^b Department of Clinical Informatics, Tokyo Medical and Dental University, Tokyo, Japan

^c Medicrome, Inc., National Institute of Advanced Industrial Science and Technology, Japan

^d Biological Information Research Center, National Institute of Advanced Industrial Science and Technology, Japan

Received 18 August 2007; received in revised form 11 December 2007; accepted 8 February 2008

KEYWORDS

Influenza vaccine;
Pandemic;
H5N1;
cDNA microarray;
Safety test

Summary We propose that cDNA microarray analysis can be used in the quality control of pandemic and endemic influenza vaccine. Based on the expression profiles of 76 genes in the rat lung one day after inoculation of influenza vaccine, we can distinguish whole-virion influenza vaccine (PDv: pandemic influenza vaccine and WPv: whole particle vaccine) and sub-virion vaccine (HA vaccine) from saline. Among these 76 genes, we found genes up-regulated by influenza infection, as well as genes involved in the immune response, and interferon. Hierarchical clustering of each influenza vaccine by the expression profiles of these 76 genes matched data from current quality control tests in Japan, such as the abnormal toxicity test (ATT) and the leukopenic toxicity test (LTT). Thus, it can be concluded that cDNA microarray technology is an informative, rapid and highly sensitive method with which to evaluate the quality of influenza vaccines. Using DNA microarray system, consistent with the results of the ATT and LTT, it was clarified that there was no difference in vaccine quality between PDv and WPv.
© 2008 Elsevier Ltd. All rights reserved.

Introduction

Influenza virus triggers a highly contagious acute respiratory illness, which can lead to high fever, muscle aches, sore throat, non-productive cough, and sometimes lead to death.

* Corresponding author. Tel.: +81 42 561 0771.

E-mail address: kyama@nih.go.jp (K. Yamaguchi).

¹ These authors contributed equally to this work.

Influenza virus is a member of the *Orthomyxoviridae* family and is divided into Type A, B and C viruses. Type A influenza viruses are candidates for annual epidemic and occasional pandemics, and are sub-divided by hemagglutinin (HA) and neuraminidase (NA) [1]. Among the various types of HA, H1 and H3 subtypes are found in human and mutations in these enable the virus to evade the immune system. Recently, a highly pathogenic avian influenza A virus (H5N1) has been identified in poultry, migratory birds and human beings, which has resulted in severe disease or death around the world. As of August 16, 2007, there have been 321 confirmed human cases of avian influenza A (H5N1) reported to the WHO and 194 of these have died [2]. Although transmission from human to human is inefficient and limited, the virus has the potential to cause the next influenza pandemic, and it is essential to prepare for such a possible pandemic [3]. Among various strategies for dealing with this possibility, vaccination is the principal defense strategy for reducing morbidity and mortality during a pandemic. However, conventional split influenza vaccines might be unsuitable against a pandemic caused by influenza type H5N1. Thus, development of a pandemic influenza vaccine is urgently required. The Japanese Ministry of Health Labour and Welfare (MLHW) have released guidelines for fast-track licensing of pandemic influenza vaccine. During the pre-pandemic period, submission of a mock-up pandemic vaccine were formally assessed and approved by national regulatory authorities.

Several influenza vaccines are now being developed and pre-clinically and clinically assessed by several vaccine manufacturers around the world [4]. In clinical trials, an immune response is induced by two shots of high doses of an inactivated sub-virion vaccine based on H5N1 virus isolated in 2004 [5,6] and a recombinant hemagglutinin based on H5N1 virus isolated in 1997 [7]. To induce a high level of immunity after one dose, several countries have tried to develop a whole-virion vaccine. Whole-virion vaccines are more immunogenic than split-virion vaccines [8]; however the reactogenicity of whole-virion vaccines is higher than that of split vaccines [9]. A clinical trial in China clearly showed that antibody responses were well induced after the first dose, and that no serious adverse event was reported [10]. Despite the evidence that there are differences in immunogenicity and reactogenicity between whole and sub-virion vaccines, there have been few pre-clinical trials and animal safety tests. It is important to address whether pre-clinical and animal safety tests can predict and correlate to clinical trials [11], and a rapid and more sensitive safety test must be developed.

In Japan, the MLHW decided to develop and save whole-virion H5N1 vaccine adjuvanted with aluminum hydroxide. In Japan, as in other countries, all vaccines for human use must conform to the "Minimum Requirements for Biological Products" and are obliged to pass national control tests [12]. Quality control of influenza vaccines is performed by the abnormal toxicity test (ATT) and the leukopenic toxicity test (LTT), which are based on body weights and peripheral white blood cell (WBC) counts in mice after subcutaneous or intra-peritoneal injection [13,14]. However, it was not known whether these tests (ATT and LTT) could evaluate the safety of pandemic influenza vaccine, and these tests require a lot of animals and days. In addition, several researchers have discussed the safety of aluminum adjuvant-containing

influenza vaccines [15]. Although aluminum hydroxide is thought to be safe and has long been used as a vaccine adjuvant, aluminum adjuvants have resulted in macrophagic myofasciitis and delayed-type hypersensitivity [16]. Thus, we must investigate the safety and toxicity of whole-virion H5N1 vaccine adjuvanted with aluminum hydroxide.

In this study, we compare pandemic vaccine (PDv; whole-virion H5N1 vaccine adjuvanted with aluminum hydroxide), whole virion-particle vaccine (WPv) without any adjuvant, and HA vaccine (HAV). In addition, to develop rapid and more sensitive and reproducible methods, we performed a comprehensive gene expression analysis of rats after administration of the various type of influenza vaccine, using DNA microarrays. Our previous study clearly shows that cDNA microarrays are a useful technology with which to evaluate the safety and quality of pertussis vaccine, and we can successfully identify the genes related to vaccine toxicity [17]. In the present study, we developed the cDNA microarray technology and applied it to the safety evaluation of influenza A/Vietnam/1194/2004 (H5N1) vaccines.

Materials and methods

Animals

Male Fisher-344 (F344) rats (8 weeks) were obtained from SLC (Tokyo, Japan). All animals were housed in rooms maintained at 23 ± 1 °C, with 50 ± 10% relative humidity, and 12-h light: 12-h dark cycles, at least 1 week prior to the test challenge. Rats typically weighed 160–200 g on arrival.

Vaccines

The following vaccines were used in this study. (1) PDv: inactivated monovalent A/H5N1 whole-virion influenza vaccine (derived from NIBRG-14: A/Vietnam/1194/2004) adjuvanted with aluminum hydroxide, containing 30 µg HA/ml. NIBRG-14 is constructed by reverse genetics, using A/Vietnam/1194/2004 and PR-8 (H1N1). (2) WPv: inactivated whole trivalent influenza vaccines (A/Newcaledonia/20/99 (H1N1), A/Hiroshima/52/2005 (H3N2), and B/Malaysia/2506/2004), containing 30 µg HA/ml each strain. (3) HAv: trivalent HA influenza vaccine (A/Newcaledonia/20/99 (H1N1), A/Hiroshima/52/2005 (H3N2), and B/Malaysia/2506/2004), containing 30 µg HA/ml each strain. All vaccines were produced and manufactured by The Chemo-Sero-Therapeutic Research Institute, Kaketsuken (Kumamoto, Japan). All vaccines complied with the minimum requirement for biological products in Japan. Each 5 ml vaccine was intra-peritoneally (*i.p.*) injected into rats. Five milliliters of saline (SA) (Otsuka normal saline; Otsuka Pharmaceutical Factory, Inc., Naruto, Tokushima, Japan) was intra-peritoneally injected as a control.

Abnormal toxicity test and leukopenic toxicity test

According to the minimum requirement for biological products in Japan [12], we performed an abnormal toxicity test and a leukopenic toxicity test for influenza vaccine (PDv,

Please cite this article in press as: Mizukami T, et al. Application of complementary DNA microarray technology to influenza A/Vietnam/1194/2004 (H5N1) vaccine safety evaluation. *Vaccine* (2008), doi:10.1016/j.vaccine.2008.02.031

Application of complementary DNA microarray technology to influenza A/Vietnam/1194/2004 (H5N1) vaccine safety evaluation3

120 WPv, HAV and SA). We used healthy rats showing no sign
 121 of disease and normal increases in body weight during a
 122 7-day quarantine period before injection. Each 5 ml vac-
 123 cine was intra-peritoneally (*i.p.*) injected into five rats. Five
 124 milliliters of saline was intra-peritoneally injected as a con-
 125 trol. We checked the body weights of rats for 4 days. For
 126 the LTT, peripheral blood was collected from tail vein at
 127 2, 16, 48, 72 and 96 h after virus vaccine injection. Immedi-
 128 ately, we counted the number of peripheral blood leukocytes
 129 (PBL), mean corpuscular hemoglobin (HGB), red blood cells
 130 (RBC), hematocrit (HCT), mean corpuscular volume (MCV)
 131 and platelets (PLT), using an automatic haematocytome-
 132 ter, the Celltac MEK-5254 (Nihon Kohden, Tokyo, Japan).
 133 To assess the significance of differences, a z-test for ATT
 134 data and a Student's *t*-test for LTT data were performed
 135 according to the minimum requirements for biological prod-
 136 ucts in Japan [12]. Spearman's rank correlation coefficient
 137 *r* was calculated. All statistical analyses were performed by
 138 GraphPad Prism (version 4, GraphPad Software, San Diego,
 139 CA).

140 **Histology**

141 Animals were anesthetized with diethylether and the
 142 brains, thymuses, lungs, livers, spleens, pancreases, small
 143 intestines, kidneys, testes and bone marrows were col-
 144 lected. Tissues were fixed with Bouin's solution (Sigma, St.
 145 Louis, MO) and 4% (w/v) paraformaldehyde in phosphate-
 146 buffered saline (PBS) for at 4°C for 24h. After fixation,
 147 tissues were dehydrated through a series of graded ethanols
 148 and xylene and embedded in paraffin. Tissue samples were
 149 cut into 4 μm sections and stained with hematoxylin and
 150 eosin (H.E.). Five rats per group, treated with each vaccine,
 151 were analyzed on days 1–4 post-treatment.

152 **RNA preparation**

153 Animals treated with PDv, WPv, HAV and SA were anes-
 154 thetized with diethylether and lung samples were collected.
 155 Lung samples were immediately frozen in liquid nitrogen for
 156 storage. Thawed tissue was homogenized and mixed with
 157 ISOGEN reagent (NIPPON GENE, Tokyo, Japan). Total RNA
 158 was prepared from lysates in accordance with the manufac-
 159 turer's instructions. Poly(A)+ RNA was prepared from total
 160 RNA using a Poly(A) Purist Kit (Ambion, Austin, TX), accord-
 161 ing to the manufacturer's instructions.

162 **Microarray preparation and expression profile
 163 acquisition**

164 For the microarray analysis, three lung samples from each
 165 rat were analyzed on days 1–4 post-treatment. In total 48
 166 lung samples were analyzed in this experiment.

167 A set of synthetic poly-nucleotides (80-mers) represent-
 168 ing 11,464 rat transcripts derived from 10,490 independent
 169 genes, and including most of the RefSeq clones deposited
 170 in the NCBI database (MicroDiagnostic, Tokyo, Japan), was
 171 arrayed on aminosilane-coated glass slides (Type I; Mat-
 172 sunami, Kishiwada, Japan) using a custom-made arrayer
 173 [18,19]. Poly(A)+ RNA (2 μg) from each sample was labeled

with Cyanine 5-dUTP (PerkinElmer, Boston, MA) using Super-
 Script II (Invitrogen, Carlsbad, CA); a common rat reference
 RNA (MicroDiagnostic) was labeled with Cyanine 3-dUTP
 (PerkinElmer, Boston, MA). Labeling, hybridization and
 washes of microarrays were performed using a Labeling &
 Hybridization Kit (MicroDiagnostic) according to the manu-
 facturer's instructions. The rat common reference RNA was
 purchased as a single batch and labeled as an aliquot with
 Cyanine-3 for hybridization to a single microarray side by
 side with each sample labeled with Cyanine-5. Hybridization
 signals were measured using a GenePix 4000A scanner (Axon
 Instruments, Whipple Road Union City, CA) and then pro-
 cessed into primary expression ratios ([Cyanine 5-intensity
 obtained from each sample]/[Cyanine 3-intensity obtained
 from common reference RNA]), which are indicated as
 'median of ratios' in GenePix Pro 3.0 software (Axon Instru-
 ments)). Normalization was performed for the median of
 ratios (primary expression ratios) by multiplying normaliza-
 tion factors calculated for each feature on a microarray by
 the GenePix Pro 3.0 software.


194 **Data analysis**

195 Data processing and hierarchical cluster analysis were per-
 196 formed using Excel (Microsoft, Tokyo, Japan) and an MDI
 197 gene expression analysis software package (MicroDiagnos-
 198 tic). The primary expression ratios were converted into log₂ Q4
 199 values (log₂ Cyanine-5 intensity/Cyanine-3 intensity) (des-
 200 ignated log ratios) and compiled into a matrix (designated
 201 primary data matrix). To predict the most obvious differ-
 202 ences obtained from cluster analysis of the primary data
 203 matrix, we extracted 5346 genes with log₂ ratios over 1
 204 or under -1 in at least one sample from the primary data
 205 matrix and subjected them to two-dimensional hierarchi-
 206 cal cluster analysis for samples and genes. To identify genes
 207 demonstrating significant changes in expression, we under-
 208 took the following: (i) mean averages of log₂ ratios were
 209 calculated for each gene from data sets of day 1 SA- and
 210 WPv-treated samples; (ii) standard deviations were calcu-
 211 lated for each gene; (iii) the difference in mean averages
 212 between day 1 SA- and WPv-treated samples was calculated
 213 for each gene and divided by the sum of the corresponding
 214 standard deviation values. The difference in the mean aver-
 215 ages/the sum of the standard deviations was defined as the
 216 signal-to-noise ratio for each gene. We chose the 76 genes
 217 exhibiting the highest expression signal-to-noise indices and
 218 extracted expression data corresponding to these genes
 219 from the primary data matrix for all samples; this data
 220 was subsequently subjected to two-dimensional hierarchical
 221 cluster analysis for samples and genes.

222 **Quantitative RT-PCR analysis**

223 Changes of gene expression assessed by microarray anal-
 224 ysis were confirmed by quantitative real-time reverse
 225 transcription-polymerase chain reaction (RT-PCR) for
 226 selected 18 genes. PCR primers (Table 2) were designed Q5
 227 for 18 genes using the Primer Express software (Applied
 228 Biosystems, Foster City, CA). Total RNA was used to synthe-
 229 size first strand cDNA using a First-strand cDNA Synthesis
 230 Kit (Life Science, Inc., St. Petersburg, FL), according

Please cite this article in press as: Mizukami J, et al.: Application of complementary DNA microarray technology to influenza A/Vietnam/1194/2004 (H5N1) vaccine safety evaluation. Vaccine (2008) doi:10.1016/j.vaccine.2008.02.031



Mizukami et al., Application of Complementary DNA Microarray Technology to Influenza (H5N1) Vaccine Safety Evaluation

Figure 1 Influenza quality was evaluated by conventional National tests. (A) Abnormal toxicity test (left panel) and leukopenic toxicity test (right panel) for influenza vaccine (PD_v, WP_v, HA_v, and SA). Body weight changes were plotted for 4 days (left panel). Changes in body weight are indicated by the mean increase \pm S.D. in five animals. The number of WBCs (white blood cells) was plotted for 4 days (right panel). Changes in WBCs are indicated by the mean increase \pm S.D. in five animals. (B) The differences

Please cite this article in press as: Mizukami T, et al., Application of complementary DNA microarray technology to influenza A/Vietnam/1194/2004 (H5N1) vaccine safety evaluation. Vaccine (2008), doi:10.1016/j.vaccine.2008.02.031

231 to the manufacturer's instructions. Expression levels of
 232 selected genes were analyzed by quantitative (Q) reverse
 233 transcriptase-polymerase chain reaction using a 7500 Fast
 234 Real-Time PCR System (Applied Biosystems) with 7500
 235 Fast System SDS Software Version 1.3. cDNA was amplified
 236 for Q-PCR using SYBR Green I (Molecular Probes, Inc.) to
 237 detect PCR product. One microliters of six-fold diluted
 238 cDNA was used in a 20- μ l final volume reaction containing
 239 10 μ l SYBR Green[®] PCR Master Mix (Applied Biosystems),
 240 0.2 μ M forward primer, and 0.2 μ M reverse primer. The 7500
 241 Fast System was programmed to run an initial polymerase
 242 activation step at 95°C for 10 min followed by 40 cycles of
 243 denaturation (95°C for 15 s) and extension (60°C for 1 min),
 244 and product synthesis was monitored at the end of the
 245 extension step of each cycle. Each expression values were
 246 normalized against rat β -actin. Data presented in the Fig. 4
 247 are the average and standard deviation of two independent
 248 quantitative RT-PCR analysis in each sample (SA, HAV, WPv
 249 and PDv). Statistical significance was calculated using
 250 Student's two-tailed *t*-test (paired two-sample for means)
 251 between WPv- and SA-treated rat lung. To determine the
 252 correlation between DNA microarray data and quantitative
 253 RT-PCR analysis, a Pearson correlation coefficient was
 254 calculated.

255 Results

256 Abnormal toxicity test for H5N1 influenza vaccine

257 Animals were treated with 5 ml of pandemic influenza
 258 vaccine (PDv; whole-virion H5N1 vaccine adjuvanted with
 259 aluminum hydroxide), whole virion-particle vaccine (WPv)
 260 without any adjuvant, HA vaccine (HAV) or saline as a control,
 261 and the body weight [BW] of each rat was checked
 262 at days 1, 2, 3 and 4. Five rats per group were analyzed
 263 each day after intraperitoneal (*i.p.*) injection of vaccine or
 264 saline. In SA- and HAV-treated animals, no decrease in the
 265 body weight (BW) was observed, and there were no significant
 266 differences in body weight changes between SA- and
 267 HAV-treated animals for 4 days (Fig. 1A). Decrease rate in BW
 268 was significantly different between PDv- and WPv-treated
 269 animals and SA- and HAV-treated rats, from 16 h to 4 days
 270 ($P < 0.05$) after injections (Fig. 1A and B). When we compared
 271 the decrease rate in BWs of PDv- and WPv-treated
 272 rats, no significant differences were observed between days
 273 1 and 4. The abnormal toxicity test is a test that evaluates
 274 vaccine quality based on decreased body weights after *i.p.*
 275 injection to the animal in Japan. According to the criteria of
 276 the Japanese national regulatory test - Minimum Requirements
 277 for Biological Products [12], it can be concluded that
 278 vaccine quality in HAV is same as in the SA. However, vaccine
 279 quality in WPv and PDv were different from HAV and

SA. In addition, within WPv and PDv, there was no significant
 difference in the vaccine quality.

282 Leukopenic toxicity test for various influenza 283 vaccines

284 Animals were treated with 5 ml of PDv, WPv, HAV or SA as
 285 a control, and peripheral WBCs (white blood cells) were
 286 collected from tail veins at 2, 16, 48, 72 and 96 h after
 287 inoculation, and counted. Three rats per group, at each
 288 time point after sample *i.p.* injection, were analyzed. A
 289 reduction in WBC number was observed in all animals at
 290 2 h after *i.p.* injection of SA, HAV, WPv and PDv. However,
 291 the decrease in the number of WBCs continued and a significant
 292 decrease in WBC number ($P < 0.05$) was observed in
 293 WPv- and PDv-treated animals, compared with SA- and HAV-
 294 treated animals, at 16 h after *i.p.* injection (Fig. 1A and B).
 295 In addition, a significant decrease ($P < 0.05$) in platelet (PLT)
 296 number was observed in WPv- and PDv-treated animals at
 297 16 h after *i.p.* injection. No significant differences of the
 298 numbers of RBCs (red blood cells), HGB (mean corpuscular
 299 hemoglobin), HCT (hematocrit), or MCV (mean corpuscular
 300 volume) were observed among all groups (*data not shown*).
 301 According to the criteria of Japanese national regulatory
 302 test-Minimum Requirements for Biological Products (12), it
 303 can be concluded that vaccine quality in HAV is same as in
 304 the SA. However, vaccine quality in WPv and PDv were different
 305 from HAV and SA. In addition, within WPv and PDv,
 306 there was no significant difference in the vaccine quality.

307 Histological analysis of influenza vaccine-treated 308 rats

309 Animals were treated with 5 ml of PDv, WPv, HAV or SA as
 310 a control, and various tissues (brain, thymus, lung, liver,
 311 spleen, kidney, testis, pancreas, and small intestine) were
 312 histologically evaluated. Among these tissues, focal necrosis
 313 (FN) of the liver was observed in the livers of both WPv- and
 314 SA-treated rats at day 1 after injection (Fig. 1C); after day
 315 2, we could not detect any FN in the liver, indicating that
 316 FN was induced by experimental stress. No histopathological
 317 changes were observed in any other tissue.

318 Microarray analysis of vaccine-treated lung

319 To evaluate the effect of influenza vaccines on gene expression
 320 in the lung, we prepared three rats per group; PDv-,
 321 WPv-, HAV- and SA-treated groups were sacrificed and
 322 lung samples were taken at days 1, 2, 3 and 4. A total
 323 of 48 independent lung tissue samples were analyzed.
 324 We labeled poly(A) + RNA purified from these samples and

among PDv-, WPv-, HAV- and SA-treated animals 16 h after vaccine injection. Significant differences in body weight changes were observed between SA- and WPv-treated rats ($P < 0.01$), SA and PDv ($P < 0.01$). Increasing and decreasing rate in body weights are indicated as a percentage (%) compared to the body weight before injection; means \pm S.D. of five animals are shown. A significant difference in the numbers of platelets (center panel) and WBCs (right panel) was observed between SA- and WPv-treated rats ($P < 0.01$), as well as between SA- and PDv-treated rats ($P < 0.01$). (C) Histological analysis of vaccine-treated rat liver. Lung and kidney at day 1 after injection. Sectioned samples were stained with H.E. and analyzed at low (upper panel) and high (lower panel) magnification. NT, non-treatment; SA, saline; HAV, HA vaccine; WPv, whole particle vaccine and PDv, pandemic vaccine.

Please cite this article in press as: Mizukami T, et al. Application of complementary DNA microarray technology to influenza A/Vietnam/1194/2004 (H5N1) vaccine safety evaluation. Vaccine (2008), doi:10.1016/j.vaccine.2008.02.031

Lung (5346 genes)


Condition: Filt: ± 1.0 , n=1

<Sample>

- Saline (SA)
- Whole virion Particle vaccine (WPv)
- HA vaccine (HAV)
- Pandemic vaccine (PDv)

<Day>


- 1day
- 2day
- 3day
- 4day



Mizukami et al., Application of Complementary DNA Microarray Technology to Influenza (H5N1) Vaccine Safety Evaluation

Figure 2 Overall gene expression profiles obtained from SA-, HAV-, WPv- and PDv-treated rat lung. Genes expressed in saline and vaccine-treated lungs are assembled in the order obtained from the results of cluster analysis. The color bar at the left shows the ratio vs the common reference RNA in log₂; red and blue indicate up and down-regulated genes, respectively. A matrix of 5346 genes that were up- or down-regulated in at least one experiment from day 1 to 4 after injection.

Please cite this article in press as: Mizukami T, et al., Application of complementary DNA microarray technology to influenza A/Vietnam/1194/2004 (H5N1) vaccine safety evaluation, Vaccine (2008), doi:10.1016/j.vaccine.2008.02.031



Mizukami et al., Application of Complementary DNA Microarray Technology to Influenza (H5N1) Vaccine Safety Evaluation

Figure 3 Microarray analysis of gene expression in the SA-, HAV-, WPv- and PDv- treated rat lung. A matrix of 76 genes regulated in at least one experiment from day 1 to 4 after injection. Hierarchical clustering of the 76 selected genes that were preferentially regulated in WPv-treated rat lung compared with SA-treated rat lung at day 1 ($P < 0.005$). ClcA, cluster A; ClcB, cluster B and ClcC, cluster C.

Please cite this article in press as: Mizukami T, et al., Application of complementary DNA microarray technology to influenza A/Vietnam/1194/2004 (H5N1) vaccine safety evaluation, Vaccine (2008) doi:10.1016/j.vaccine.2008.02.031

Q8 Table 1 Genes that were up- and down-regulated by influenza vaccine ($P < 0.005$)

Official gene name	Symbol	ID	PDv-D1 mean \pm S.D.	WPv-D1 mean \pm S.D.	HAv-D1 mean \pm S.D.	SA-D1 mean \pm S.D.
IFN-inducible gene						
Myxovirus (influenza virus) resistance 1	Mx1	X52711	6.163 \pm 0.276	5.514 \pm 0.19	2.198 \pm 0.272	0.935 \pm 0.117
Interferon regulatory factor 7	Irf7	XM_215121	5.39 \pm 0.67	5.51 \pm 0.39	2.06 \pm 0.87	0.32 \pm 0.08
Myxovirus (influenza virus) resistance 2	Mx2	NM_017028	4.08 \pm 0.13	3.83 \pm 0.06	1.14 \pm 0.41	-0.01 \pm 0.19
Interferon gamma inducible protein	Irf47	NM_172019	2.66 \pm 0.05	2.32 \pm 0.01	0.31 \pm 0.12	-0.06 \pm 0.12
FLN29 gene product	Fln29	AF329825	2.66 \pm 0.15	2.26 \pm 0.12	1.03 \pm 0.23	0.61 \pm 0.05
Similar to interferon inducible protein	Similar	XM_220360	1.84 \pm 0.23	1.74 \pm 0.06	0.61 \pm 0.15	0.45 \pm 0.05
Interferon-related developmental regulator 1	Ifrd 1	NM_019242	1.20 \pm 0.18	0.94 \pm 0.10	0.19 \pm 0.14	-0.26 \pm 0.12
Chemokine and cytokine function						
Lectin, galactoside-binding, soluble, 3 binding protein	Lgals3bp	AF065438	4.50 \pm 0.21	4.52 \pm 0.19	2.66 \pm 0.48	1.28 \pm 0.09
Tissue inhibitor of metalloproteinase 1	Timp1	NM_053819	2.75 \pm 0.12	2.66 \pm 0.22	0.78 \pm 0.39	-0.09 \pm 0.25
Chemokine (C-X-C motif) ligand 9	Cxcl9	NM_145672	2.54 \pm 0.52	2.88 \pm 0.13	0.78 \pm 0.18	0.35 \pm 0.15
Lectin, galactose binding, soluble 9	Lgals9	NM_012977	2.01 \pm 0.24	1.85 \pm 0.06	0.07 \pm 0.18	-0.65 \pm 0.20
Colony stimulating factor 1 (macrophage)	Csf1	NM_023981	1.94 \pm 0.07	1.81 \pm 0.24	0.84 \pm 0.13	0.59 \pm 0.16
Granulin	Grn	NM_017113	1.84 \pm 0.08	1.67 \pm 0.07	0.57 \pm 0.14	0.43 \pm 0.13
Chemokine (C-X-C motif) ligand 11	Cxcl11	XM_223236	1.70 \pm 0.37	1.60 \pm 0.14	1.32 \pm 0.09	0.21 \pm 0.07
EGF-containing fibulin-like extracellular matrix protein 1	Efemp1	D89730	0.28 \pm 0.18	-0.05 \pm 0.18	0.98 \pm 0.18	1.15 \pm 0.15
Immune response						
Similar to lymphocyte antigen 6 complex,	Similar	XM_216946	4.83 \pm 0.19	4.58 \pm 0.11	2.96 \pm 0.23	2.25 \pm 0.23
Ly6-C antigen	Ly6c	NM_020103	3.75 \pm 0.11	3.33 \pm 0.26	1.89 \pm 0.41	1.44 \pm 0.08
Similar to histocompatibility 2, complement	Similar	XM_215326	3.67 \pm 0.20	3.51 \pm 0.05	1.68 \pm 0.44	0.74 \pm 0.06
RT 1 class Ib locus Aw2	RT1-Aw2	NM_012645	2.93 \pm 0.00	2.60 \pm 0.06	1.29 \pm 0.23	0.74 \pm 0.05
Beta-2 microglobulin	β 2m	NM_012512	2.90 \pm 0.12	2.86 \pm 0.11	1.52 \pm 0.12	0.86 \pm 0.09
MHC class Ia protein (RT1.A1) gene, comp	RT1-A1	AF025309	2.79 \pm 0.07	2.74 \pm 0.10	1.49 \pm 0.19	0.85 \pm 0.06
Lymphocyte antigen 6 complex, locus B	Ly6b	NM_139257	2.70 \pm 0.20	1.97 \pm 0.10	0.80 \pm 0.18	0.44 \pm 0.18
Transporter 2, ATP-binding cassette, sub-family B (MDR/TAP)	Tap2	NM_032056	2.69 \pm 0.29	2.51 \pm 0.20	1.44 \pm 0.06	1.40 \pm 0.22

Please cite this article in press as: Mizukami T, et al., Application of complementary DNA microarray technology to influenza A/Vietnam/1194/2004 (H5N1) vaccine safety evaluation, Vaccine (2008), doi:10.1016/j.vaccine.2008.02.031

Application of complementary DNA microarray technology to influenza A/Vietnam/1194/2004 (H5N1) vaccine safety evaluation⁹

Table 1 (Continued)

Official gene name	Symbol	ID	PDv-D1 mean ± S.D.	WPv-D1 mean ± S.D.	HAv-D1 mean ± S.D.	SA-D1 mean ± S.D.
Complement component 2	C2	NM_172222	2.07 ± 0.10	2.00 ± 0.21	0.93 ± 0.09	0.31 ± 0.09
Proteasome (prosome, macropain) subunit, beta type 9	Psmb9	NM_012708	2.07 ± 0.13	1.73 ± 0.01	0.48 ± 0.05	0.21 ± 0.07
TAP binding protein	Tapbp	NM_033098	1.95 ± 0.13	1.63 ± 0.13	0.12 ± 0.11	-0.10 ± 0.10
RT1 class Ib gene, H2-TL-like, grc region (N3)	RT1-N3	L23128	1.62 ± 0.03	1.45 ± 0.20	0.14 ± 0.16	-0.14 ± 0.22
Proteasome (prosome, macropain) 28 subunit, alpha	Psme 1	NM_017264	1.20 ± 0.10	0.79 ± 0.01	0.06 ± 0.11	-0.63 ± 0.09
Cathepsin S	Ctss	NM_017320	0.99 ± 0.12	0.59 ± 0.17	0.03 ± 0.08	-0.42 ± 0.06
Complement component 1, s subcomponent	C1s	D88250	0.83 ± 0.07	0.82 ± 0.08	-0.93 ± 0.16	-1.90 ± 0.09
Proteasome (prosome, macropain) 28 subunit, beta	Psme2	NM_017257	0.26 ± 0.03	0.02 ± 0.15	-0.78 ± 0.23	-1.41 ± 0.22
Elastin	Eln	J04035	0.01 ± 0.21	0.08 ± 0.26	1.95 ± 0.11	1.83 ± 0.25
Fibrinogen, gamma polypeptide	Fgg	NM_012559	-2.70 ± 0.26	-2.78 ± 0.22	-3.68 ± 0.32	-3.80 ± 0.21
Transcription activity Z-DNA binding protein 1	Zbp1	AJ302054	2.73 ± 0.46	2.12 ± 0.19	1.02 ± 0.07	0.32 ± 0.15
CCAAT/enhancer binding protein (C/EBP), delta	Cebpd	NM_013154	2.58 ± 0.41	2.20 ± 0.08	1.38 ± 0.15	0.70 ± 0.22
Similar to H1 histone family, member 2;	Similar	XM_225325	1.67 ± 0.19	1.31 ± 0.06	0.21 ± 0.03	0.08 ± 0.18
Activating transcription factor 5	Atf5	NM_172336	0.95 ± 0.06	0.99 ± 0.06	0.76 ± 0.29	-0.74 ± 0.03
AHNAK nucleoprotein (desmoyokin)	Ahnak	AF454371	0.58 ± 0.21	0.36 ± 0.18	0.85 ± 0.11	1.36 ± 0.17
Nuclear protein 1 histone cluster 1, H2bl	Nupr1	AF014503	-0.74 ± 0.11	-1.09 ± 0.04	-2.78 ± 0.28	-2.83 ± 0.07
H2bl	Hist1h2bl	NM_022647	-0.95 ± 0.07	-0.93 ± 0.13	-1.77 ± 0.06	-1.98 ± 0.13
Apoptosis						
Caspase 1 (Casp1), mRNA.	Casp1	NM_012762	0.92 ± 0.13	0.91 ± 0.07	0.12 ± 0.05	-0.34 ± 0.17
Heat shock protein 27 (Hsp27) mRNA, comp	Hsp27	M86389	0.90 ± 0.14	0.84 ± 0.15	0.08 ± 0.05	-0.20 ± 0.14
Mitochondrial cytochrome oxidase subunits, I, II, III genes, 9		J01435	-3.51 ± 0.27	-3.63 ± 0.10	-1.89 ± 0.16	-2.08 ± 0.12
Protein modification						
Serine (or cysteine) peptidase inhibitor, clade G, member 1	Serping1	NM_199093	2.20 ± 0.12	2.14 ± 0.03	0.66 ± 0.16	0.08 ± 0.13
Cellular signaling						
DNA-damage inducible transcript 3	Ddit3	NM_024134	2.07 ± 0.20	1.97 ± 0.21	0.38 ± 0.22	0.30 ± 0.24
HRAS like suppressor 3	Hrasls3	NM_017060	0.98 ± 0.18	0.46 ± 0.11	-0.84 ± 0.22	-1.23 ± 0.18

Please cite this article in press as: Mizukami T, et al., Application of complementary DNA microarray technology to influenza A/Vietnam/1194/2004 (H5N1) vaccine safety evaluation, Vaccine (2008), doi:10.1016/j.vaccine.2008.02.031

Table 1 (Continued)

Official gene name	Symbol	ID	PDv-D1 mean \pm S.D.	WPv-D1 mean \pm S.D.	HA v-D1 mean \pm S.D.	SA-D1 mean \pm S.D.
Similar to signal transducer and activate	Similar	XM.222301	0.80 \pm 0.28	0.94 \pm 0.23	-0.15 \pm 0.08	-0.28 \pm 0.12
Retinoic acid receptor, beta	Rarb	AJ002942	-2.73 \pm 0.09	-2.81 \pm 0.21	-1.86 \pm 0.16	-1.61 \pm 0.22
Metabolism						
2',5'-Oligoadenylate synthetase 1, 40/46 kDa	Oas1	Z18877	4.27 \pm 0.41	4.14 \pm 0.30	1.96 \pm 0.60	1.38 \pm 0.43
Similar to 2-5 oligoadenylate synthetase	Similar	XM.222230	1.75 \pm 0.35	1.70 \pm 0.24	0.43 \pm 0.39	0.07 \pm 0.08
6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Pfkfb3	NM.057135	1.72 \pm 0.36	1.62 \pm 0.16	0.99 \pm 0.16	0.47 \pm 0.19
Carbonic anhydrase 4	Ca4	NM.019174	-0.85 \pm 0.33	-0.84 \pm 0.12	0.66 \pm 0.15	0.66 \pm 0.15
Monoglyceride lipase	Mgll	NM.138502	-0.90 \pm 0.03	-1.16 \pm 0.23	-0.43 \pm 0.05	-0.08 \pm 0.22
GTP cyclohydrolase I	Gchfr	U85512	-1.24 \pm 0.09	-1.65 \pm 0.11	-1.22 \pm 0.21	-0.49 \pm 0.22
feedback regulator						
Cytochrome b mRNA, complete cds; mitochondria	cytb	AF295545	-2.55 \pm 0.19	-2.65 \pm 0.11	-1.17 \pm 0.06	-1.30 \pm 0.14
Others						
EST351314 gene index, normalized rat, no	EST	AW920010	2.96 \pm 0.48	2.42 \pm 0.18	2.02 \pm 0.48	1.41 \pm 0.23
Nerve growth factor receptor (TNFR superfamily, member 16)	Ngfr	NM.012610	2.62 \pm 0.30	1.85 \pm 0.31	-0.25 \pm 0.43	-0.59 \pm 0.17
Cdig2 protein	Cdig2	NM.153624	2.62 \pm 0.11	2.08 \pm 0.09	0.70 \pm 0.17	0.46 \pm 0.06
Xanthine dehydrogenase	Xdh	NM.017154	2.02 \pm 0.11	1.95 \pm 0.16	0.77 \pm 0.04	0.47 \pm 0.28
EST108196 PC-12 cells, untreated cDNA cl	EST	AA685798	1.92 \pm 0.11	1.69 \pm 0.07	0.54 \pm 0.07	0.30 \pm 0.10
Similar to torsin family 3, member A; AT	Similar	XM.222769	1.76 \pm 0.08	1.48 \pm 0.35	0.02 \pm 0.38	-0.14 \pm 0.20
Glypican 3	Gpc3	NM.012774	1.61 \pm 0.08	1.46 \pm 0.23	2.62 \pm 0.57	2.71 \pm 0.13
Similar to RIKEN cDNA 2310008M14 [Mus mu	Similar	XM.217259	1.58 \pm 0.02	1.55 \pm 0.14	0.58 \pm 0.20	0.13 \pm 0.04
Similar to peanut-like 2 homolog; peanut	Similar	XM.213413	1.38 \pm 0.15	1.33 \pm 0.07	2.20 \pm 0.18	2.33 \pm 0.09
Solute carrier family 3 (activators of dibasic and neutral amino acid transport), member	Slc3a2	NM.019283	1.21 \pm 0.13	0.75 \pm 0.07	-0.14 \pm 0.28	-0.38 \pm 0.6
UI-R-A1-em-f-05-0-UI.s1 UI-R-A1 cDNA clo	EST	AA925529	1.15 \pm 0.13	0.82 \pm 0.07	-0.06 \pm 0.15	-0.54 \pm 0.14
Superoxide dismutase 2, mitochondrial	Sod2	NM.017051	0.86 \pm 0.09	0.60 \pm 0.11	-0.77 \pm 0.35	-1.04 \pm 0.04

Please cite this article in press as: Mizukami T, et al., Application of complementary DNA microarray technology to influenza A/Vietnam/1194/2004 (H5N1) vaccine safety evaluation, Vaccine (2008), doi:10.1016/j.vaccine.2008.02.031

Application of complementary DNA microarray technology to influenza A/Vietnam/1194/2004 (H5N1) vaccine safety evaluation 11

Table 1 (Continued)

Official gene name	Symbol	ID	PDv-D1 mean ± S.D.	WPv-D1 mean ± S.D.	HAv-D1 mean ± S.D.	SA-D1 mean ± S.D.
Clusterin	Clu	NM_012679	0.78 ± 0.09	0.74 ± 0.09	-0.21 ± 0.16	-0.37 ± 0.16
DnaJ (Hsp40) homolog, subfamily A, member 1	Dnaja1	NM_022934	0.72 ± 0.16	0.66 ± 0.12	-0.26 ± 0.09	-0.42 ± 0.10
Similar to growth hormone inducible tran solute carrier family 28	Similar	XM_214285	0.49 ± 0.08	0.26 ± 0.17	-0.47 ± 0.25	-0.80 ± 0.09
Solute carrier family 28	Slc28a2	NM_031664	0.16 ± 0.16	0.01 ± 0.09	-0.71 ± 0.26	-1.15 ± 0.19
Sodium channel, voltage-gated, type VII, alpha	Scn7a	Y09164	-0.39 ± 0.25	-0.48 ± 0.14	0.09 ± 0.41	0.54 ± 0.03
EST224035 Normalized spleen, Bento Soare	EST	AI180292	-2.20 ± 0.34	-1.64 ± 0.20	-4.02 ± 0.30	-2.94 ± 0.25
smooth muscle alpha-actin	Acta2	M22757	-2.77 ± 0.24	-2.34 ± 0.09	-1.18 ± 0.25	-1.17 ± 0.05
Solute carrier family 3, member 1	Slc3a1	NM_017216	-3.10 ± 0.66	-3.56 ± 0.21	-2.92 ± 0.65	-2.40 ± 0.23
S100 calcium binding protein G	S100g	NM_012521	-3.93 ± 0.29	-3.72 ± 0.22	-2.17 ± 0.15	-2.10 ± 0.18

Cyanine 5-labeled lung RNA and Cyanine 3-labeled rat common reference RNA were competitively hybridized to a DNA microarray. Hybridization signals were processed into primary expression ratio ([Cyanine5- intensity obtained from each sample]/[Cyanine3- intensity obtained from each sample]), and normalized (primary expression ratio). The primary expression ratios were converted into log₂ values (log₂ Cyanine5-intensity/log₂ Cyanine3-intensity). Log₂ values for each sample were averaged and S.D. values were calculated. SA, Saline; HAV, HA vaccine; WPv, whole particle vaccine, PDv, pandemic vaccine.

325 from a rat common reference RNA with Cyanine-5 and
326 Cyanine-3, respectively. Next, we hybridized labeled RNAs
327 to microarrays representing 11,464 transcripts derived from
328 10,490 independent genes, including most of the RefSeq
329 clones deposited in the NCBI database. Hybridization sig-
330 nals were processed into expression ratios as log₂ values
331 (designated log₂ ratios). To predict the most obvious dif-
332 ferences obtained from cluster analysis of the primary data
333 matrix, we extracted 5346 genes with log₂ ratios over 1
334 or under -1 in at least one sample from the primary data
335 matrix. When we performed a cluster analysis for 5346 tran-
336 scripts, two large clusters were obtained, and whole-virion
337 vaccines (1 day after PDv- and WPv-treated) showed dif-
338 ferent clusters from the others (HAV and SA) (Fig. 2). To
339 evaluate the differences in gene expression between those
340 induced by whole-virion vaccines and those induced by oth-
341 ers (HAV and SA), we extracted 76 genes essential for class
342 separation ($P < 0.005$). When we performed a cluster anal-
343 ysis of these 76 genes, three large clusters were obtained.
344 These 76 genes can distinguish whole-virion vaccines (PDv-
345 and WPv-treated samples (day 1 and day 2)) from the oth-
346 ers (HAV and SA) (Fig. 3). The three clusters formed by
347 these 76 genes include: cluster A, whole virion-treated lung
348 at day 1; cluster B, whole virion-treated lung at day 2;
349 and cluster C, sub-virion and SA-treated rat lung at day
350 1. These 76 genes are listed in Table 1. Among these 76
351 genes, we found that the genes up-regulated by influenza
352 infection included interferon-stimulated genes (ISGs), such
353 as *Mx1* (myxovirus (influenza virus) resistance 1), *Irf47*
354 (interferon gamma inducible protein 47), *Irfd1* (interferon-
355 related developmental regulator 1), *FLN29* (FLN29 gene

product) and *Cxcl9* (chemokine (C-X-C motif) ligand 9), as
shown in Table 1. In addition, genes up-regulated by the
immune response and antigen presentation, including *Ctss*
(cathepsin S), *Psme1* (proteasome (prosome, macropain) 28
subunit, alpha), *Psme2* (proteasome (prosome, macropain)
28 subunit, beta), *Tap2* (transporter 2, ATP-binding cassette,
sub-family B (MDR/TAP)), *Tapbp* (TAP binding protein) *RT1-
Aw2* (RT1 class Ib, locus Aw2), *RT1-N3* (RT1 class Ib gene,
H2-TL-like, grc region (N3)) and *β2m* (β2 microglobulin),
were also strongly induced in whole-virion-treated rat lung.

To confirm and validate our DNA microarray analysis, we
selected subset of 18 genes (Table 2), and performed quan-
titative RT-PCR analysis. Data presented in the Fig. 4 are
the average, standard deviation and correlation between
two independent quantitative RT-PCR and DNA microarray
analysis in each sample (SA, HAV, WPv and PDv). As a result
of comparison between two detection methods, Pearson's
correlation coefficient indicates a statistically significant
correlation between DNA microarray and quantitative RT-
PCR analysis among our selected 18 genes. This correlation
demonstrates excellent concordance between two methods.
In addition, significant difference between WPv and SA was
also observed in quantitative RT-PCR analysis ($P < 0.05$ [Stu-
dent *t*-test]), similar to DNA microarray analysis.

These data suggest that vaccine quality in WPv and PDv
were different from HAV. In addition, within WPv and PDv,
there was no significant difference in the vaccine quality
using DNA microarray analysis. Thus, it can be concluded
that cDNA microarray technology is an informative, rapid
and highly sensitive method with which to evaluate the
quality of influenza vaccines. Using DNA microarray system,

Please cite this article in press as: Mizukami T, et al. Application of complementary DNA microarray technology to influenza A/Vietnam/1194/2004 (H5N1) vaccine safety evaluation. Vaccine (2008) doi:10.1016/j.vaccine.2008.02.031

Table 2

Number	Gene name	Forward	Reverse
NM_012512	β 2m	TTGAGCTACTGAAGAATGAAAGAAGA	GGTGGGTGTGAATTCAGTGTGA
NM_172222	C2	TTGTGCCTAGGGACTTCCACAT	GGCAAAAAGTCGAGGACACCAT
NM_145672	Cxcl9	TTTGCCCAAGCCCTAACTG	TGGGTCTAGGCAGGTTTGATCTC
AF329825	FLN29	CCGGAGGAAGTCTCATTGA	GAAGAGTCCAGTATTGAGTGAAC
XM_215121	Irf7	TGCAGCGTGAGGGTGTGTC	TCATCGTAGAGACTATTGGTGCTAGACA
AF065438	Lgals3bp	TCTACCTCACCACCTCACTGACA	CAGGCTGCTGGAGGTTCCCT
NM_172019	Irf47	CCTAGCCAACCAGGAAATGAAT	GGGAGTTTGGTGAAGGACAA
NM_019242	Ifrd1	GCAGTACCCTTGACAGACAAATGAAT	AAGTGTTCAGCATCGAGCATC
L23128	RT1-N3	AGTGCTTCTTGTCTGGCATTCT	AATGAGGTGTGTGAGAGGATGGAG
NM_017028	Mx2	AAGGAACATAGTGACACCAGTGAGAAG	GGACAGGGCCAGCTTAACCA
NM_012708	Psmb9	CTCTGGCCATGAACCGAGAT	CAGCTCGTCTCCCAGGATGA
NM_017264	Psme1	ATCTATTGAGCCCCCTCTCTCGTT	GGGTGCAGTCTAGAGTTCCCTAGTCA
AF025309	RT1-A1	CCTGCCTGTGTTCCCTTCCA	CAAGGAGTGACAGGATGCAGATGT
NM_012645	RT1 -Aw2	TGCCTGAGCCCTTTCCC	CCACAGCTCCAAGAACAACAGAA
XM_223236	Cxch 1	CTGAAGGCTCATAAAGGACAAAGGT	CACATGTTCTGGCGCCTTAA
NM_033098	Tapbp	GACCGTTCCAAAGACGAAAAG	TGGAGTCGTTTGACCAGAGAT
NM_053819	Timp1	CCTGTTCAGCCATCCCTTGC	GCCCCTCAGAGCCCATGA
AJ302054	Zbp1	TTAGTAGTAGCCCCCAGAGTCAA	ACCTACGGTGGATGGTCATCTT
NM_031144	P-actin	ACCGTGAAAAGATGACCCAGATC	GACCAGAGGCATACAGGGACAAC

387 consistent with the results of the ATT and LTT, there was
388 no difference in global gene expression in the lung between
389 PDv and WPv.

390 **Discussion**

391 Recently, quality assurance of the vaccines was rigorously
392 controlled according to the good manufacturing practices
393 (GMP), process validation, inspection and tests of the
394 national regulator authority (NRA) in Japan and similar bod-
395 ies in other countries. Current quality control and safety
396 tests, such as the abnormal toxicity test and the leukopenic
397 toxicity test, are useful to evaluate influenza vaccine safety
398 for 50 years. ATT (also known as the general safety test or
399 Q6 inocuity test) is a test for extraneous toxic contaminants in
400 other countries. However, in Japan, the ATT is an established
401 test that can evaluate vaccine quality based on changes in
402 body weight over a period of 7 days after inoculation of
403 final container vaccine compared to the trend data from
404 past quality control test, statistically. These trend data was
405 constructed at least 100 lot of each vaccine, which have
406 already passed by the ATT and for which safety has been
407 determined after post marketing surveillance. Whereas the
408 ATT is a useful and long-performed test, the mechanism of
409 the ATT was not well defined until recently [17]. In addition,
410 inherent toxicity of vaccines and the intra-peritoneal injec-
411 tion root have been raised. For this reason, the relevance
412 of the ATT has been questioned by some regulatory authori-
413 ties. Currently, the FDA is discussing whether to abolish the
414 requirement for the ATT, and the EMEA (European Agency for
415 the Evaluation of Medicinal Products) has already decided to
416 abolish the ATT for testing vaccines for human use.


417 In this study, we developed a new quality control method
418 for influenza vaccine using DNA microarrays. We successfully
419 translated the vaccine quality, immunogenicity and reacto-
420 genicity of influenza vaccine into gene expression profile

data. According to the ATT, decrease in the body weight
was only observed in whole virion-treated rats, and these
tests did not distinguish PDv from WPv. Giving the same
results as the ATT, the LTT showed that whole virion is dif-
ferent from sub-virion influenza vaccine, and there is no
difference in vaccine quality between PDv and WPv. In the
DNA microarray system, consistent with the results of the
ATT and LTT, whole virion-treated rat lung was located in a
different cluster from sub-virion- and SA-treated rat lung.
Using gene expression profiles, we could not distinguish PDv
from WPv. These data suggest that the DNA microarray sys-
tem is not only equivalent to the ATT and LTT, but is also
more informative. More interestingly, intra-peritoneal injec-
tion of influenza vaccine induced gene expression related to
the immune response in a manner to be described below.
These data predict that ATT and LTT are useful to evaluate
the immunogenicity and reactogenicity, and intra-peritoneal
injection can induce normal immunity. Moreover, using the
DNA microarray system, the effect of vaccine treatment
could be determined and substituted by gene expression
profile changes.

In general, quality of gene expression data obtained
from cDNA microarray has varied with platform and pro-
cedures used and validation of cDNA microarray should
be required for eliminate the effect of dye biases [20].
Our cDNA microarray method have been performed and
validated by several different researchers, samples and
condition [21–24]. In previous report, we performed two
independent experiments of cDNA microarray and they are
validated with another method of real-time PCR and *in situ*
hybridization [17]. Real-time PCR is often referred to as a
gold standard for gene expression measurement and valida-
tion of DNA microarray [25]. As a result of our validation,
we have shown that there is a strong correlation between
cDNA microarray and real-time-PCR analysis. These reports
suggest that our cDNA microarray method have high repro-
ducibility, reliability for the vaccine quality control. In this

421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457

Please cite this article in press as: Mizukami T, et al., Application of complementary DNA microarray technology to influenza A/Vietnam/1194/2004 (H5N1) vaccine safety evaluation, Vaccine (2008), doi:10.1016/j.vaccine.2008.02.031



Mizukami et al., Application of Complementary DNA Microarray Technology to Influenza (H5N1) Vaccine Safety Evaluation

Figure 4 Comparison of cDNA microarray and quantitative real-time-PCR analysis. Expression of selected 18 genes from DNA microarray analysis (bar) is compared with real-time quantitative PCR data (dot) within the same pareto graph. Bar represented relative log₂ ratios (average ± S.D.) that extracted from the secondary data matrix for each selected genes (left side). Dot represented expression level (average ± S.D.) of selected genes relative to rat β-actin derived from two independent quantitative RT-PCR analysis (right side). A Pearson correlation coefficient was shown within each pareto graphs. Significant correlation between DNA microarray and quantitative PCR analysis was observed in our selected genes.

458 study, we have designed our experiment in same way of
459 our previous research and also done real-time PCR analy-
460 sis for 18 genes and yield statistically significant correlation
461 between cDNA microarray and real-time PCR. These data
462 have suggested that our cDNA microarray method for evalu-
463 ating vaccine quality is reliable and validated.

464 Based on the changes in the expression profiles of 76
465 genes, we can distinguish whole-virion influenza vaccine
466 (PDV: pandemic influenza vaccine and WPV: whole partic-
467 le vaccine) from sub-virion vaccine (HAV: HA vaccine) and
468 saline (Fig. 3). Among the 76 genes we extracted, we found
469 that some genes were already reported as the endemic and
470 pandemic influenza virus infection-inducing genes. The
471 most common gene that influenza infection and vaccination
472 induced was *Mx1* (myovirus (influenza virus) resistance
473 1). *Mx1* is an IFN-stimulated gene (ISG) and is induced by
474 interferon (IFN) in many species. Some Mx GTPases have

475 antiviral activity against a wide range of RNA viruses, includ-
476 ing influenza viruses and members of the bunyavirus family
477 [26]. Human influenza (H1N1 A/Texas/36/91) infection in
478 lung [27] and 1918 pandemic influenza virus infection in
479 bronchi [28] both induced MX (homologue of murine *Mx1*)
480 genes, as shown by cDNA microarray analysis in Macaques.
481 In the human middle ear epithelial cells, infection with
482 influenza A/Alaska (6/77) (H3N2) also induced *Mx1* [29].
483 In our experiment, *Mx1* expression was highly induced in
484 whole-virion influenza vaccine-treated rat lung, but not in
485 sub-virion vaccine-treated rat lung. These data suggest that
486 *Mx1* is one of the most promising biomarkers with which
487 to evaluate influenza vaccine quality, and whole-virion vac-
488 cines have the same immunogenicity as influenza infection
489 in the lung.

490 Similar to the influenza infection, other ISGs, *Ifi47*
491 [30], *Ifrd1* [31], and the gamma interferon-induced

Please cite this article in press as: Mizukami T, et al., Application of complementary DNA microarray technology to influenza A/Vietnam/1194/2004 (H5N1) vaccine safety evaluation. Vaccine (2008), doi:10.1016/j.vaccine.2008.02.031

monokine *Cxcl9* (chemokine (C-X-C motif) ligand), were up regulated in whole-virion influenza vaccine-treated rat lung (Table 1). *Cxcl9* was induced by influenza infection in primary human umbilical vein endothelial cells (HUVECs) [32]. *Cxcl9*, which is a ligand of *Cxcr3*, stimulated the directional migration of activated CD8+ T cells to the lung, and contributed significantly to the accumulation of cytotoxic T lymphocytes (CTL) in the lung [33]. In addition, in the first case of H5N1 influenza infection in January 2003, patients with H5N1 disease had unusually high serum concentrations of *Cxcl9* and *IP-10* [34]. These data strongly suggest that whole-virion influenza vaccine induces proinflammatory cytokines like influenza A (H5N1) infection, and that *Cxcl9* is a common molecule related to influenza pathology and toxicity.

Among our extracted 76 genes, antigen modification and presentation-related genes, including *Ctss* (cathepsin S), *Psme1* (proteasome (prosome, macropain) 28 subunit, alpha), *Psme2* (proteasome (prosome, macropain) 28 subunit, beta), *Tap2* (transporter 2, ATP-binding cassette, sub-family B (MDR/TAP)), *Tapbp* (TAP (transporter associated with antigen processing)-binding protein), *RT1-Aw2* (RT1 class Ib, locus Aw2), *RT1-N3* (also known as MHC class I) and $\beta 2m$ (beta2-microglobulin), were up-regulated in PDv- and WPv-treated rat lung. *Tapbp* has an affinity to bind *Tap2*, which is a member of the family of ABC transporters and transports peptides from the cytosol into the endoplasmic reticulum for binding to MHC class I and $\beta 2m$ complex molecules for subsequent viral antigen presentation [35]. *RT1-Aw2* and *RT1-N3* form a MHC complex and $\beta 2m$ enhances the MHC stability and antigenicity of suboptimal CTL epitopes. These four genes have a major role of antigen presentation to CD8-T cells [36]. These data suggest that whole-virion vaccine more strongly induced CTL than sub-virion vaccine. These evidences support that whole-virion influenza vaccines have high immunogenicity than HA vaccine, and our method can potentially evaluate the effectiveness and efficacy of the vaccine by monitoring the expression of these genes. Further analyses are required whether these genes expression correlated to the antibody response and efficacy of influenza vaccine.

Among our screened genes, *Timp1* is induced by whole-virion influenza vaccine. *Timp1* (tissue inhibitor of metalloproteinase 1) is a member of the physiological inhibitors of matrix metalloproteinases (MMPs) and is produced in the respiratory tract on the development of airway inflammation and remodeling in the lung [37]. Recently, it was proposed that an imbalance between serum MMP-9 and TIMP-1 damages the blood-brain barrier and promotes febrile seizures or encephalopathy in cases of influenza virus infection [38]. These data suggest that *Timp1* up-regulation could be a possible phenotypic marker of toxicity related to encephalopathy. Acute disseminated encephalomyelitis (ADEM) and Guillain-Barre Syndrome (GBS) are both observed in 10–20 cases per 1 million adults and are most important issue in influenza vaccine safety [39]. In the United States, it was reported that highest number of GBS cases occurred in patients receiving an influenza vaccine followed by hepatitis vaccine [40]. Our data help us to understand the mechanism of adverse event in the vaccine injection. Further analysis will be required to determine whether up-regulation of these genes was

observed in a particular lot of influenza vaccine, resulting in encephalopathy.

The most concerning matter is whether safety of aluminum adjuvanted pandemic influenza vaccine can be evaluated or not in this system. Using current quality control tests, such as the ATT, LTT and even more histological analysis, there was no significant difference in vaccine quality between PDv- and WPv-treated rats at any time point (Fig. 1A and C). In the DNA microarray system, there was no difference between PDv- and WPv-treated rats. These data strongly suggest that the vaccine quality of whole-virion vaccine with or without aluminum hydroxide were unchanged in the lung. These data might be helpful to understand the safety of aluminum hydroxide. More interestingly, it has been proposed that strain is a key factor in the influenza vaccine. Comparing H5N1 and H1N1, no difference in vaccine quality was observed using DNA microarray analysis. These data strongly suggest that strain differences do not affect vaccine basal quality and that the type of vaccine, whether whole virion or sub-virion, is a main issue to induce high immunity if the influenza type for vaccine production matched to endemic or pandemic influenza infection.

Thus, it may be concluded that cDNA microarray technology is an informative, rapid and highly sensitive method with which to evaluate endemic and pandemic influenza vaccine quality. These findings suggest that our new method have a potential to shorten the time for the safety tests and can reduce the number of animals used. In addition, our test may contribute to the development of urgently required vaccine. Further analyses are required to confirm these gene expression changes correlate to the vaccine quality. At any rate, in terms of sensitivity and the amount of information available from one animal test, this method may be even better than current safety tests.

We previously reported several pertussis vaccine toxicity-related genes and proposed DNA microarray analysis as a new model for quality control tests [17]. In this study, we again proposed that DNA microarray analysis have a potential for the quality control of pandemic and endemic influenza vaccines.

Acknowledgements

We are grateful to Dr. Masato Tashiro, National Institute of Infectious Diseases, Japan for our research coordination and constructive discussion. *Funding:* This work was supported by Grants-in-Aid from Ministry of Health, Labour and Welfare, Japan.

References

- [1] Lamb RA, Krug RM. Orthomyxoviridae: the viruses and their replication. In: Knipe DM, Howley PM, editors. Fields virology. New York: Lippincott-Raven Press; 2000. p. 1487–531.
- [2] WHO website. http://www.who.int/csr/disease/avian_influenza/country/cases.table_2007_06_29/en/index.html.
- [3] Ungchusak K, Auewarakul P, Dowell SF, Kitphati R, Auwanit W, Puthavathana P, et al. Probable person-to-person transmission of avian influenza A (H5N1). *N Engl J Med* 2005;352(4):333–40.
- [4] Stephenson I, Gust I, Pervikov Y, Kienny MP. Development of vaccines against influenza H5. *Lancet Infect Dis* 2006;6(8):458–60.

Please cite this article in press as: Mizukami T, et al.: Application of complementary DNA microarray technology to influenza A/Vietnam/1194/2004 (H5N1) vaccine safety evaluation. *Vaccine* (2008) doi:10.1016/j.vaccine.2008.02.031

- 611 [5] Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety
612 and immunogenicity of an inactivated subvirion influenza A
613 (H5N1) vaccine. *N Engl J Med* 2006;354(13):1343-51.
- 614 [6] Bresson JL, Perronne C, Launay O, Gerdil C, Saville M,
615 Wood J, et al. Safety and immunogenicity of an inactivated
616 split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine:
617 phase I randomised trial. *Lancet* 2006;367(9523):1657-
618 64.
- 619 [7] Treanor JJ, Wilkinson BE, Maseoud F, Hu-Primmer J, Battaglia
620 R, O'Brien D, et al. Safety and immunogenicity of a recombi-
621 nant hemagglutinin vaccine for H5 influenza in humans. *Vaccine*
622 2001;19(13-14):1732-7.
- 623 [8] Wright PF, Dolin R, La Montagne JR. From the National Institute
624 of Allergy and Infectious Diseases of the National Institutes of
625 Health, the Center for Disease Control, and the Bureau of Bio-
626 logicals of the Food and Drug Administration. Summary of clinical
627 trials of influenza vaccines—II. *J Infect Dis* 1976;134(6):633-
628 8.
- 629 [9] Cate TR, Couch RB, Kasel JA, Six HR. Clinical trials of mono-
630 valent influenza A/New Jersey/76 virus vaccines in adults:
631 reactogenicity, antibody response, and antibody persistence.
632 *J Infect Dis* 1977;136(Suppl.):450-5.
- 633 [10] Lin J, Zhang J, Dong X, Fang H, Chen J, Su N, et al. Safety
634 and immunogenicity of an inactivated adjuvanted whole-virion
635 influenza A (H5N1) vaccine: a phase I randomised controlled
636 trial. *Lancet* 2006;368(9540):965-6.
- 637 [11] Subbarao K, Luke C. H5N1 viruses and vaccines. *PLoS Pathog*
638 2007;3(3):e40.
- 639 [12] Minimal Requirements for Biological Products, National Insti-
640 tute of Infectious Diseases Japan; 2006. See website
641 <http://www.nih.go.jp/niid/MRBP/index-e.html>.
- 642 [13] Kurokawa M, Ishida S, Asakawa S, Iwasa S, Goto N, Kuratsuka K.
643 Toxicities of influenza vaccine: peripheral leukocytocrespon-
644 ce to live and inactivated influenza viruses in mice. *Jpn J Med Sci*
645 *Biol* 1975;28:37-52.
- 646 [14] Chino F. The views and policy of the Japanese control authori-
647 ties on the three Rs. *Dev Biol Stand* 1996;86:53-62.
- 648 [15] Authier FJ, Gherardi RK. Safety and immunogenicity of H5N1
649 vaccine. *Lancet* 2006;367(9523):1657-64.
- 650 [16] Exley C. Aluminium-containing DTP vaccines. *Lancet Infect Dis*
651 2004;4:324 (Discussion 325).
- 652 [17] Hamaguchi I, Imai J, Momose H, Kawamura M, Mizukami T,
653 Kato H, et al. Two vaccine toxicity-related genes Agp and Hpx
654 could prove useful for pertussis vaccine safety control. *Vaccine*
655 2007;25(17):3355-64.
- 656 [18] Kobayashi S, Ito E, Honma R, Nojima Y, Shibuya M, Watanabe
657 S, et al. Dynamic regulation of gene expression by the Flt-
658 1 kinase and Matrigel in endothelial tubulogenesis. *Genomics*
659 2004;84(1):185-92.
- 660 [19] Ito E, Honma R, Imai J, Azuma S, Kanno T, Mori S, et
661 al. A tetraspanin-family protein, T-cell acute lymphoblas-
662 tic leukemia-associated antigen 1, is induced by the Ewing's
663 sarcoma-Wilms' tumor 1 fusion protein of desmoplastic small
664 round-cell tumor. *Am J Pathol* 2003;163(6):2165-72.
- 665 [20] Churchill GA. Fundamentals of experimental design for cDNA
666 microarrays. *Nat Genet* 2002;32:490-5.
- 667 [21] Ito E, Honma R, Yanagisawa Y, Imai J, Azuma S, Oyama T, et al.
668 Novel clusters of highly expressed genes accompany genomic
669 amplification in breast cancers. *FEBS Lett* 2007;581:3909-14.
- 670 [22] Miura A, Honma R, Togashi T, Yanagisawa Y, Ito E, Imai
671 J, et al. Differential responses of normal human coronary
672 artery endothelial cells against multiple cytokines com-
673 paratively assessed by gene expression profiles. *FEBS Lett*
674 2006;580(30):6871-9.
- 675 [23] Fujita N, Miyamoto T, Imai J, Hosogane N, Suzuki T, Yagi
676 M, et al. CD24 is expressed specifically in the nucleus pul-
677 posus of intervertebral discs. *Biochem Biophys Res Commun*
678 2005;338(4):1890-6.
- 679 [24] Sakamoto A, Imai J, Nishikawa A, Honma R, Ito E, Yanagisawa
680 Y, et al. Influence of inhalation anesthesia assessed by compre-
681 hensive gene expression profiling. *Gene* 2005;356:39-48.
- 682 [25] Shi L, Tong W, Fang H, Scherf U, Han J, Puri RK, et al.
683 Cross-platform comparability of microarray technology: intra-
684 platform consistency and appropriate data analysis procedures
685 are essential. *BMC Bioinform* 2005;6(Suppl. 2):S12.
- 686 [26] Haller O, Staeheli P, Kochs G. Interferon-induced Mx proteins
687 in antiviral host defense. *Biochimie* 2007;89(6-7):812-8.
- 688 [27] Baskin CR, Garcia-Sastre A, Tumpey TM, Bielefeldt-Ohmann
689 H, Carter VS, Nistal-Villan E, et al. Integration of clinical
690 data, pathology, and cDNA microarrays in influenza virus-
691 infected pigtailed macaques (*Macaca nemestrina*). *J Virol*
692 2004;78(19):10420-32.
- 693 [28] Kobasa D, Jones SM, Shinya K, Kash JC, Copps J, Ebihara
694 H, et al. Aberrant innate immune response in lethal infec-
695 tion of macaques with the 1918 influenza virus. *Nature*
696 2007;445(7125):319-23.
- 697 [29] Tong HH, Long JP, Li D, DeMaria TF. Alteration of gene expres-
698 sion in human middle ear epithelial cells induced by influenza
699 A virus and its implication for the pathogenesis of otitis media.
700 *Microb Pathog* 2004;37(4):193-204.
- 701 [30] Ishiguro N, Takada A, Yoshioka M, Ma X, Kikuta H, Kida H, et
702 al. Induction of interferon-inducible protein-10 and monokine
703 induced by interferon-gamma from human endothelial cells
704 infected with Influenza A virus. *Arch Virol* 2004;149(1):17-34.
- 705 [31] Mashima R, Saeki K, Aki D, Minoda Y, Takaki H, Sanada T, et al.
706 FLN29, a novel interferon- and LPS-inducible gene acting as a
707 negative regulator of toll-like receptor signaling. *J Biol Chem*
708 2005;280(50):41289-97.
- 709 [32] Collazo CM, Yap GS, Sempowski GD, Lusby KC, Tessarollo L,
710 Woude GF, et al. Inactivation of LRG-47 and IRG-47 reveals
711 a family of interferon gamma-inducible genes with essential,
712 pathogen-specific roles in resistance to infection. *J Exp Med*
713 2001;194(2):181-8.
- 714 [33] Agostini C, Faccio M, Siviero M, Carollo D, Galvan S, Cattelan
715 AM, et al. CXC chemokines IP-10 and mig expression and direct
716 migration of pulmonary CD8+/CXCR3+ T cells in the lungs of
717 patients with HIV infection and T-cell alveolitis. *Am J Respir*
718 *Crit Care Med* 2000;162:1466-73.
- 719 [34] Peiris JS, Yu WC, Leung CW, Cheung CY, Ng WF, Nicholls JM,
720 et al. Re-emergence of fatal human influenza A subtype H5N1
721 disease. *Lancet* 2004;363(9409):617-9.
- 722 [35] Tewari MK, Sinnathamby G, Rajagopal D, Eisenlohr LC. A
723 cytosolic pathway for MHC class II-restricted antigen pro-
724 cessing that is proteasome and TAP dependent. *Nat Immunol*
725 2005;6(3):287-94.
- 726 [36] Uger RA, Chan SM, Barber BH. Covalent linkage to beta2-
727 microglobulin enhances the MHC stability and antigenicity of
728 suboptimal CTL epitopes. *J Immunol* 1999;162(10):6024-8.
- 729 [37] Gueders MM, Foidart JM, Noel A, Cataldo DD. Matrix met-
730 alloproteinases (MMPs) and tissue inhibitors of MMPs in the
731 respiratory tract: potential implications in asthma and other
732 lung diseases. *Eur J Pharmacol* 2006;533:133-44.
- 733 [38] Ichiyama T, Morishima T, Kajimoto M, Matsushige T, Matsubara
734 T, Furukawa S. Matrix metalloproteinase-9 and tissue inhibitors
735 of metalloproteinases 1 in influenza-associated encephalopa-
736 thy. *Pediatr Infect Dis J* 2007;26(6):542-4.
- 737 [39] Ropper AH, Victor M. Influenza vaccination and the Guillain-
738 Barre syndrome. *N Engl J Med* 1998;339(25):1845-6.
- 739 [40] Souayah N, Nasar A, Suri MF, Qureshi AI. Guillain-Barre syn-
740 drome after vaccination in United States a report from the
741 CDC/FDA Vaccine Adverse Event Reporting System. *Vaccine*
742 2007;25(29):5253-5.

Please cite this article in press as: Mizukami T, et al., Application of complementary DNA microarray technology to influenza A/Vietnam/1194/2004 (H5N1) vaccine safety evaluation, *Vaccine* (2008), doi:10.1016/j.vaccine.2008.02.031